TNF inhibitors, the original biologic agents ... as compared with every 12 weeks with a drug like risankizumab [Skyrizi]," she said. "Patients really love that because they can kind of live ...

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...

TNF inhibitors used in these patients included ... In the IL-23 inhibitor class were guselkumab (Tremfya), tildrakizumab (Ilumya), and risankizumab (Skyrizi), as well as the dual IL-12/23 ...

In pregnancy, any anti-TNF alpha, vedolizumab, ustekinumab and risankizumab is safe to use in pregnancy and lactation. We want to avoid the use of S1P inhibitors as well as JAK inhibitors.

Initiated the Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS) and the Phase 3 ...

and the other focusing on TNF-IR patients while being the first trial to include risankizumab as an active reference arm (IZAR-2) Initiated three new trials in the beginning of 2025 with the Nanobody ...

while IZAR-2 is expected to enroll patients with an inadequate response to tumor necrosis factor-α inhibitors (TNF-IR) — reflecting patients commonly seen in clinical practice — and is the ...

compared with patients who stayed on full-dose TNF inhibitors. Medscape Medical News, November 08, 2021 ACR 2021 Risankizumab Outperforms Placebo at 6 Months for Psoriatic Arthritis At the 24-week ...

and the other focusing on TNF-IR patients while being the first trial to include risankizumab as an active reference arm (IZAR-2) Initiated three new trials in the beginning of 2025 with the ...

Skyrizi (risankizumab) is the first IL-23-selective ... integrin inhibitors – as well as older branded and biosimilar TNF inhibitors including AbbVie's own blockbuster Humira (adalimumab).